Verve Therapeutics Future Growth
Future criteria checks 0/6
Verve Therapeutics's earnings are forecast to decline at 11.2% per annum while its annual revenue is expected to grow at 5.1% per year. EPS is expected to decline by 2.3% per annum. Return on equity is forecast to be -89% in 3 years.
Key information
-11.2%
Earnings growth rate
-2.3%
EPS growth rate
Biotechs earnings growth | 24.2% |
Revenue growth rate | 5.1% |
Future return on equity | -89.0% |
Analyst coverage | Good |
Last updated | 14 Jun 2024 |
Recent future growth updates
Recent updates
Why Verve Therapeutics Deserves A Spot On Your Watchlist
Jun 13Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher
May 14The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing
Aug 24Verve Therapeutics jumps 75% in its first day of trading
Jun 17Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 21 | -283 | -231 | -271 | 5 |
12/31/2025 | 11 | -260 | -230 | -209 | 8 |
12/31/2024 | 15 | -224 | -212 | -186 | 11 |
3/31/2024 | 16 | -197 | -150 | -144 | N/A |
12/31/2023 | 12 | -200 | -159 | -150 | N/A |
9/30/2023 | 8 | -193 | -154 | -142 | N/A |
6/30/2023 | 5 | -192 | -173 | -159 | N/A |
3/31/2023 | 3 | -179 | -152 | -138 | N/A |
12/31/2022 | 2 | -157 | -136 | -122 | N/A |
9/30/2022 | 1 | -148 | -127 | -117 | N/A |
6/30/2022 | N/A | -125 | -117 | -110 | N/A |
3/31/2022 | N/A | -137 | -102 | -96 | N/A |
12/31/2021 | N/A | -120 | -82 | -78 | N/A |
9/30/2021 | N/A | -113 | -69 | -65 | N/A |
6/30/2021 | N/A | -99 | -54 | -50 | N/A |
3/31/2021 | N/A | -53 | -47 | -44 | N/A |
12/31/2020 | N/A | -46 | -39 | -35 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VERV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VERV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VERV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VERV's revenue (5.1% per year) is forecast to grow slower than the US market (8.7% per year).
High Growth Revenue: VERV's revenue (5.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VERV is forecast to be unprofitable in 3 years.